Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Raffaella Sordella, Daphne W. Bell, Daniel A. Haber and Jeffrey Settleman
Science
New Series, Vol. 305, No. 5687 (Aug. 20, 2004), pp. 1163-1167
Stable URL: http://www.jstor.org/stable/3837624
Page Count: 5
  • More info
  • Cite this Item
Preview not available
Preview not available

Abstract

Gefitinib (Iressa, AstraZeneca Pharmaceuticals) is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) and induces dramatic clinical responses in nonsmall cell lung cancers (NSCLCs) with activating mutations within the EGFR kinase domain. We report that these mutant EGFRs selectively activate Akt and signal transduction and activator of transcription (STAT) signaling pathways, which promote cell survival, but have no effect on extracellular signal-regulated kinase signaling, which induces proliferation. NSCLC cells expressing mutant EGFRs underwent extensive apoptosis after small interfering RNA-mediated knockdown of the mutant EGFR or treatment with pharmacological inhibitors of Akt and STAT signaling and were relatively resistant to apoptosis induced by conventional chemotherapeutic drugs. Thus, mutant EGFRs selectively transduce survival signals on which NSCLCs become dependent inhibition of those signals by gefitinib may contribute to the drug's efficacy.

Page Thumbnails

  • Thumbnail: Page 
1163
    1163
  • Thumbnail: Page 
1164
    1164
  • Thumbnail: Page 
1165
    1165
  • Thumbnail: Page 
1166
    1166
  • Thumbnail: Page 
1167
    1167